258 related articles for article (PubMed ID: 29899382)
21. Bcl-xL acts as an inhibitor of IP
Rosa N; Ivanova H; Wagner LE; Kale J; La Rovere R; Welkenhuyzen K; Louros N; Karamanou S; Shabardina V; Lemmens I; Vandermarliere E; Hamada K; Ando H; Rousseau F; Schymkowitz J; Tavernier J; Mikoshiba K; Economou A; Andrews DW; Parys JB; Yule DI; Bultynck G
Cell Death Differ; 2022 Apr; 29(4):788-805. PubMed ID: 34750538
[TBL] [Abstract][Full Text] [Related]
22. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function.
Monaco G; La Rovere R; Karamanou S; Welkenhuyzen K; Ivanova H; Vandermarliere E; Di Martile M; Del Bufalo D; De Smedt H; Parys JB; Economou A; Bultynck G
FEBS J; 2018 Jan; 285(1):127-145. PubMed ID: 29131545
[TBL] [Abstract][Full Text] [Related]
23. BDA-366, a putative Bcl-2 BH4 domain antagonist, induces apoptosis independently of Bcl-2 in a variety of cancer cell models.
Vervloessem T; Sasi BK; Xerxa E; Karamanou S; Kale J; La Rovere RM; Chakraborty S; Sneyers F; Vogler M; Economou A; Laurenti L; Andrews DW; Efremov DG; Bultynck G
Cell Death Dis; 2020 Sep; 11(9):769. PubMed ID: 32943617
[TBL] [Abstract][Full Text] [Related]
24. The Bcl-2 protein family member Bok binds to the coupling domain of inositol 1,4,5-trisphosphate receptors and protects them from proteolytic cleavage.
Schulman JJ; Wright FA; Kaufmann T; Wojcikiewicz RJH
J Biol Chem; 2013 Aug; 288(35):25340-25349. PubMed ID: 23884412
[TBL] [Abstract][Full Text] [Related]
25. The type 2 inositol 1,4,5-trisphosphate receptor, emerging functions for an intriguing Ca²⁺-release channel.
Vervloessem T; Yule DI; Bultynck G; Parys JB
Biochim Biophys Acta; 2015 Sep; 1853(9):1992-2005. PubMed ID: 25499268
[TBL] [Abstract][Full Text] [Related]
26. The BH4 domain of Bcl-2 orthologues from different classes of vertebrates can act as an evolutionary conserved inhibitor of IP
Ivanova H; Luyten T; Decrock E; Vervliet T; Leybaert L; Parys JB; Bultynck G
Cell Calcium; 2017 Mar; 62():41-46. PubMed ID: 28179071
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
[TBL] [Abstract][Full Text] [Related]
28. A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma.
Luo Q; Pan W; Zhou S; Wang G; Yi H; Zhang L; Yan X; Yuan L; Liu Z; Wang J; Chen H; Qiu M; Yang D; Sun J
Oncol Res; 2020 Sep; 28(4):331-344. PubMed ID: 32093809
[TBL] [Abstract][Full Text] [Related]
29. Cancer cell death strategies by targeting Bcl-2's BH4 domain.
de Ridder I; Kerkhofs M; Veettil SP; Dehaen W; Bultynck G
Biochim Biophys Acta Mol Cell Res; 2021 Apr; 1868(5):118983. PubMed ID: 33549704
[TBL] [Abstract][Full Text] [Related]
30. Inositol 1,4,5-trisphosphate receptor-isoform diversity in cell death and survival.
Ivanova H; Vervliet T; Missiaen L; Parys JB; De Smedt H; Bultynck G
Biochim Biophys Acta; 2014 Oct; 1843(10):2164-83. PubMed ID: 24642269
[TBL] [Abstract][Full Text] [Related]
31. Selective regulation of IP3-receptor-mediated Ca2+ signaling and apoptosis by the BH4 domain of Bcl-2 versus Bcl-Xl.
Monaco G; Decrock E; Akl H; Ponsaerts R; Vervliet T; Luyten T; De Maeyer M; Missiaen L; Distelhorst CW; De Smedt H; Parys JB; Leybaert L; Bultynck G
Cell Death Differ; 2012 Feb; 19(2):295-309. PubMed ID: 21818117
[TBL] [Abstract][Full Text] [Related]
32. Rhomboid pseudoproteases: An Achilles heel's for BCL-2/IP
Lemos FO; de Ridder I; Bultynck G; Parys JB
Cell Calcium; 2022 Jun; 104():102593. PubMed ID: 35525223
[TBL] [Abstract][Full Text] [Related]
33. Bcl-2-Protein Family as Modulators of IP
Ivanova H; Vervliet T; Monaco G; Terry LE; Rosa N; Baker MR; Parys JB; Serysheva II; Yule DI; Bultynck G
Cold Spring Harb Perspect Biol; 2020 Apr; 12(4):. PubMed ID: 31501195
[TBL] [Abstract][Full Text] [Related]
34. New Insights in the IP
Parys JB; Vervliet T
Adv Exp Med Biol; 2020; 1131():243-270. PubMed ID: 31646513
[TBL] [Abstract][Full Text] [Related]
35. Alpha-helical destabilization of the Bcl-2-BH4-domain peptide abolishes its ability to inhibit the IP3 receptor.
Monaco G; Decrock E; Nuyts K; Wagner LE; Luyten T; Strelkov SV; Missiaen L; De Borggraeve WM; Leybaert L; Yule DI; De Smedt H; Parys JB; Bultynck G
PLoS One; 2013; 8(8):e73386. PubMed ID: 24137498
[TBL] [Abstract][Full Text] [Related]
36. DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition.
Kerkhofs M; Vervloessem T; Stopa KB; Smith VM; Vogler M; Bultynck G
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708132
[TBL] [Abstract][Full Text] [Related]
37. The IP3 receptor as a hub for Bcl-2 family proteins in cell death control and beyond.
Parys JB
Sci Signal; 2014 Feb; 7(312):pe4. PubMed ID: 24518292
[TBL] [Abstract][Full Text] [Related]
38. Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma.
Bucher P; Erdmann T; Grondona P; Xu W; Schmitt A; Schürch C; Zapukhlyak M; Schönfeld C; Serfling E; Kramer D; Grau M; Klener P; Lengerke C; Schulze-Osthoff K; Lenz G; Hailfinger S
Blood; 2020 Jan; 135(2):121-132. PubMed ID: 31794606
[TBL] [Abstract][Full Text] [Related]
39. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma.
Lee JS; Tang SS; Ortiz V; Vo TT; Fruman DA
Oncotarget; 2015 Nov; 6(34):35202-17. PubMed ID: 26460954
[TBL] [Abstract][Full Text] [Related]
40. Remodeling of Ca
Ando H; Kawaai K; Bonneau B; Mikoshiba K
Adv Biol Regul; 2018 May; 68():64-76. PubMed ID: 29287955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
